Advancements in artificial intelligence, machine learning, and computing technologies have fueled progress in the use of sophisticated computational modeling and simulation as a tool for facilitating preclinical and clinical research in rare diseases.
In this white paper, we explore the promise of in silico approaches to rare disease drug development and share real world scenarios where the use of digital patients can help to inform study design and accelerate the approval of new therapeutics.